Market research
BPN.F Medibio Limited
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.54
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.54
About
About Medibio Limited
Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. It has a clinical trial agreement with MedBridge Healthcare LLC to support sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BPN.F discussion.
5 years, 5 months ago
Medibio Limited is currently in a long term downtrend where the price is trading 51.4% below its 200 day moving average.
From a valuation standpoint, the stock is 95.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 63.0.
Finally, its free cash flow grew by 85.8% to $-195K since the same quarter in the previous year.
Based on the above factors, Medibio Limited gets an overall score of 2/5.